
    
      Patients with advanced nasopharyngeal cancer will be randomized to 2 arms. The patients in
      experimental arm will be treated with Nimotuzumab which will be used concurrently with
      radiotherapy and chemotherapy. The chemotherapy regimen were Cisplatin monotherapy. The
      active comparator arm will be administered chemotherapy and radiotherapy only. The dose and
      regimen were the same with experiment arm. The patients'hematopoietic , hepatic and renal
      function tests will be monitored weekly, a physical exam and reassessment of the tumor will
      be performed at the first and the fourth month, and followup every six months to evaluate the
      survival index in three years after the study.
    
  